AIDS Treatment News logo      

September 17, 2009

GSK's second integrase inhibitor looks potent and well-tolerated in early study

"The experimental integrase inhibitor S/GSK1265744, which is being developed as a backup to S/GSK1349572 (GSK-572), also demonstrated high potency and good tolerability in early studies, researchers reported this week at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco."

Read more in Aidsmap, September 17, 2009.